Barcelona Liver Bioservices (BLB) announced today the presentation of a poster describing the mechanisms of action of emricasan in liver cirrhosis at the 69th annual meeting of the American Association for the Study of the Liver (AASLD), held in San Fransico, CA.

Poster #1344 “Molecular Mechanisms Underlying the Beneficial Effects of Emricasan in Portal Hypertension and Chronic Liver Disease: Relevance of the Hepato-Sinusoidal Cross-Talk” will be displayed from 14:00 – 19:30h and presented by Zoe Boyer, Associate Scientist at BLB. The study investigates the underlying mechanisms of emricasan improving portal hypertension and fibrosis in pre-clinical models of advanced chronic liver disease. Characterization of hepatocytes and non-parenchymal cells from cirrhotic rats treated with emricasan evidenced a global improvement in cells phenotype. Indeed, and compared to vehicle, hepatocytes exhibited improved synthetic function and expression of key markers, liver sinusoidal endothelial cells had a vasodilator phenotype, hepatic stellate cells became de-activated and macrophages polarized towards a pro-restorative phenotype. Further in vitro experiments confirmed that cirrhotic hepatocytes directly treated with emricasan exhibited significantly improved phenotype, which paracrinally ameliorated liver sinusoidal endothelial cells, macrophages and especially hepatic stellate cells. These paracrine effects were not related to a possible abrogation of apoptotic bodies release by hepatocytes due to emricasan, but to a modification in their secretome machinery.

Importantly, the effects of emricasan improving hepatocytes phenotype were validated in human cirrhotic cells using ExoLiver®, BLB’s proprietary model that mimics the human sinusoid in vitro.

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Inventiva, a clinical stage biopharmaceutical company with expertise in fibrosis, oncology and orphan diseases.

Under the terms of the agreement, which combines the scientific and technical expertise of both companies, BLB will perform cutting-edge research to understand the mechanisms underlying the beneficial effects of Inventiva’s lead compound lanifibranor on liver cirrhosis and portal hypertension. The research plan incorporates different BLB’s models of liver disease, including the unique ExoLiver® platform, to obtain consistent pre-clinical data.

For more information about the services and research developed by BLB please visit www.liver.barcelona

The study describes the benefits of using the ExoLiver® platform to simulate the human liver sinusoid on a chip.
View full article

Barcelona Liver Bioservices (BLB) announced today the presentation of a poster introducing the BLB’s proprietary experimental model of nonalcoholic steatohepatitis (NASH) at the 42nd annual meeting of the Spanish Association for the Study of the Liver (AEEH), held in Madrid, Spain.

Poster #10 “Introducing a new pre-clinical rat model of steatohepatitis that mimics the main characteristics of the human disease” will be displayed from 9:30 – 11h and presented by Dr Jordi Gracia, CEO and CSO of BLB. The study demonstrates that rats undergoing a new multi-hit protocol that combines the administration of pro-inflammatory toxicants and high fat high cholesterol diet for 10 weeks exhibit marked NASH, as demonstrated by the presence of hepatic steatosis (>70% hepatocytes with lipid droplets), metabolic syndrome (impaired glucose tolerance), a NAS score of 8.00, hepatic inflammation (lobular inflammation, macrophage infiltration and increased MDA), significant fibrosis (+450% in collagen, activation of hepatic stellate cells), and portal hypertension and hepatic microcirculatory dysfunction.

BLB’s proprietary animal model of NASH, termed BarNa model®, is being developed to fill an experimental gap when investigating NASH at the bench-side: the lack of a reliable experimental model of NASH that mimics the four major characteristics of the human disease: steatosis & metabolic syndrome, inflammation, significant fibrosis, and portal hypertension. BLB is currently finalizing the characterization of the BarNa model®, which will be incorporated to the portfolio of the company in 3Q 2018.

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.

For more information about the company, current partners and available research services please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB) announced today a non-exclusive partnership with the biopharmaceutical company Gilead Sciences to characterize the effects of novel chemical entities developed by Gilead for the treatment of liver diseases, including nonalcoholic steatohepatitis (NASH).

“We are eager about our collaboration with Gilead” said Jordi Gracia-Sancho, BLB’s chief scientific officer. “Gilead has recognized the value and potential of our complete pre-clinical solution to accelerate the development of new therapeutics for liver diseases”.

Under the terms of the agreement, BLB will combine its diverse pre-clinical models of liver disease, including the BLB proprietary platform ExoLiver®, to ascertain the efficacy and the underlying molecular mechanisms of Gilead’s best-in-class compounds as novel treatments for chronic liver disease and NASH.

For more information about the services and research developed by BLB please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB), CRO specialized in the design and development of pre-clinical research in hepatology, announced today a non-exclusive partnership with BrudyLab to explore Brudy’s lead compound DHA as novel therapeutic option for liver disease.

In the initial phase of the collaboration, BLB will investigate the effects and underlying mechanisms of Brudy-DHA in pre-clinical models of chronic liver disease.

For more information about the services and research developed by BLB please visit www.liver.barcelona

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in hepatology, announced today a non-exclusive collaboration with Conatus Pharmaceuticals, biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.

Under the terms of the agreement, which combines the scientific and technical expertise of both companies, BLB will perform cutting-edge research to understand the mechanisms underlying the beneficial effects of Conatus’ lead compound emricasan on liver cirrhosis and portal hypertension.

For more information about the services and research developed by BLB please visit www.liver.barcelona

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

This spin-off is born in part thanks to the CaixaImpulse program, the program of scientific entrepreneurs of La Caixa Foundation and La Caixa Capital Risk. The main asset of the company is an in vitro co-culture microfluidic liver system that mimics the microenvironment of the liver. This device, termed ExoLiver, allows maintaining the phenotype and function of human hepatic cells in culture during long periods of time and in better conditions than the conventional methods of culture. This maintenance of liver function in vitro allows studies of efficacy of drugs and toxicity in a microenvironment as close as possible to the human liver. “The characteristics of the device make it a model of high value within the pre-clinical phases of the development of new drugs in the field of liver disease,” explains Jordi Gracia-Sancho.

The device was developed by the teams of Jordi Gracia, Rosa Villa and Carmen Peralta of the institutions IDIBAPS, CSIC, CIBEREHD, Hospital Clínic and University of Barcelona, and has been licensed to BLB. “It should be noted that the potential and benefits of the device have been recognized both inside and outside our borders: it was selected by oral presentation in plenary session of the annual congress of the American Association for the Study of the Liver (AASLD), was awarded at the competition of innovation organized by VHIR- Biocat-Roche, and was selected in the 2016 CaixaImpulse program, among others” the co-founders point out.

The final aim of BLB is to offer this, and other products designed for pre-clinical research in hepatology, to pharmaceutical companies, small biotechs, CROs and research groups, to ultimately foster the development of new chemical entities to treat liver disease.